{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:07:30Z","timestamp":1765807650761,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3506-x","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T11:18:43Z","timestamp":1542194323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7149","authenticated-orcid":false,"given":"Cho","family":"Naing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kew Siang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"3506_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1089\/aid.1994.10.1409","volume":"10","author":"MR Hilleman","year":"1994","unstructured":"Hilleman MR. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different. AIDS Res Hum Retrovir. 1994;10:1409\u201319.","journal-title":"AIDS Res Hum Retrovir"},{"key":"3506_CR2","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","volume":"360","author":"C Thio","year":"2002","unstructured":"Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter AIDS cohort study (MACS). Lancet. 2002;360:1921\u20136.","journal-title":"Lancet"},{"key":"3506_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","volume":"19","author":"D Konopnicki","year":"2005","unstructured":"Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593\u2013601.","journal-title":"AIDS"},{"issue":"1 Suppl","key":"3506_CR4","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","volume":"44","author":"MJ Alter","year":"2006","unstructured":"Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6\u20139.","journal-title":"J Hepatol"},{"key":"3506_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkn175","volume":"62","author":"V Soriano","year":"2008","unstructured":"Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"S5","key":"3506_CR6","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1002\/hep.22883","volume":"49","author":"Chloe L. Thio","year":"2009","unstructured":"Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49.","journal-title":"Hepatology"},{"issue":"7474","key":"3506_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.329.7474.1080","volume":"329","author":"R Aggarwal","year":"2004","unstructured":"Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ. 2004;329(7474):1080\u20136.","journal-title":"BMJ"},{"key":"3506_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","volume":"358","author":"Y Benhamou","year":"2001","unstructured":"Benhamou Y, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus:an open-label pilot study. Lancet. 2001;358:718\u201323.","journal-title":"Lancet"},{"key":"3506_CR9","unstructured":"AIDSinfo. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/25\/hbv-hiv Accessed 23 May 2018."},{"key":"3506_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"3506_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods"},{"key":"3506_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/M15-0930","volume":"162","author":"JE Cornell","year":"2015","unstructured":"Cornell JE. The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses. Ann Intern Med. 2015;162:797\u20138.","journal-title":"Ann Intern Med"},{"key":"3506_CR13","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org . Accessed 9 Mar 2018."},{"key":"3506_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1086\/314942","volume":"180","author":"GJ Dore","year":"1999","unstructured":"Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus\/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999;180:607\u201313.","journal-title":"J Infect Dis"},{"key":"3506_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3851\/IMP1645","volume":"15","author":"A Avihingsanon","year":"2010","unstructured":"Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napisianant N, et al. Efficacy of tenofovir disoproxil fumarate\/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther. 2010;15:917\u201322.","journal-title":"Antivir Ther"},{"key":"3506_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, Juni P, Moher D, Oxman AD, et al. Cochrane Bias methods group; Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3506_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ, for the GRADE working group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"3506_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64:1277\u201382.","journal-title":"J Clin Epidemiol"},{"key":"3506_CR19","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon B-H, Shin I-S, Bae J-M. Network meta-analysis: application and practice using Stata. Epidemiology and Health. 2017;39:e2017047.","journal-title":"Epidemiology and Health"},{"key":"3506_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"3506_CR21","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.","journal-title":"PLoS One"},{"key":"3506_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3:111\u201325.","journal-title":"Res Synth Methods"},{"key":"3506_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344 [Corrigendum to \u201cAdvances in the GRADE approach to rate the certainty in estimates from a network meta-analysis\u201d [J Clin Epidemiol 2018;93:36\u201344].","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"3506_CR24","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9(7):e99682.","journal-title":"PLoS One"},{"key":"3506_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1086\/380398","volume":"189","author":"GJ Dore","year":"2004","unstructured":"Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and \u2013experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185\u201392.","journal-title":"J Infect Dis"},{"key":"3506_CR26","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/hep.21388","volume":"44","author":"MG Peters","year":"2006","unstructured":"Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44:1110\u20136.","journal-title":"Hepatology"},{"key":"3506_CR27","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/hep.22462","volume":"48","author":"GV Matthews","year":"2008","unstructured":"Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat R, et al. A randomized trial of combination hepatitis B therapy in HIV\/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48:1062\u20139.","journal-title":"Hepatology"},{"key":"3506_CR28","doi-asserted-by":"publisher","first-page":"e0134539","DOI":"10.1371\/journal.pone.0134539","volume":"10","author":"L Gu","year":"2015","unstructured":"Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, et al. Emergence of lamivudine-resistant hbv during antiretroviral therapy including lamivudine for patients coinfected with HIV and HBV in China. PLoS One. 2015;10:e0134539.","journal-title":"PLoS One"},{"key":"3506_CR29","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/infdis\/jiw439","volume":"214","author":"L Wang","year":"2016","unstructured":"Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, et al. Hepatitis B virus (HBV) load response to 2 antiviral regimens, tenofovir\/lamivudine and lamivudine, in HIV\/HBV-coinfected pregnant women in Guangxi, China: the Tenofovir in pregnancy (TiP) study. J Infect Dis. 2016;214:1695\u20139.","journal-title":"J Infect Dis"},{"key":"3506_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1086\/593104","volume":"47","author":"CJ Hoffmann","year":"2008","unstructured":"Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a south African ART program. Clin Infect Dis. 2008;47:1479\u201385.","journal-title":"Clin Infect Dis"},{"key":"3506_CR31","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1086\/525857","volume":"46","author":"S Gutierrez","year":"2008","unstructured":"Gutierrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, et al. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Clin Infect Dis. 2008;46:e28\u201330.","journal-title":"Clin Infect Dis"},{"key":"3506_CR32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/135965350801300510","volume":"13","author":"K Lacombe","year":"2008","unstructured":"Lacombe K, Gozlan J, Boyd A, Boelle PY, Bonnard P, Malean JM, et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIVHBV-coinfected patients. Antivir Ther. 2008;13:705\u201313.","journal-title":"Antivir Ther"},{"key":"3506_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/QAD.0b013e3282f303bf","volume":"22","author":"R Nuesch","year":"2008","unstructured":"Nuesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, et al. Interruptions of tenofovir\/emtricitabine-based antiretroviral therapy in patients with HIV\/hepatitis B virus co-infection. AIDS. 2008;22:152\u20134.","journal-title":"AIDS"},{"key":"3506_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1468-1293.2008.00683.x","volume":"10","author":"G Alvarez-Uria","year":"2009","unstructured":"Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Med. 2009;10:269\u201373.","journal-title":"HIV Med"},{"key":"3506_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1086\/605675","volume":"49","author":"J Idoko","year":"2009","unstructured":"Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49:1268\u201373.","journal-title":"Clin Infect Dis"},{"key":"3506_CR36","doi-asserted-by":"crossref","unstructured":"Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic outcome of using tenofovir\/emtricitabine to treat hepatitis b in hiv-coinfected patients. ISRN Gastroenterol. 2011;405390.","DOI":"10.5402\/2011\/405390"},{"key":"3506_CR37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1097\/QAD.0b013e328349bbf3","volume":"25","author":"GV Matthews","year":"2011","unstructured":"Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G, et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV\/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011;25:1727\u201335.","journal-title":"AIDS"},{"key":"3506_CR38","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/jac\/dks130","volume":"67","author":"M Nelson","year":"2012","unstructured":"Nelson M, Amaya G, Clumeck N, da Cunha CA, Jayaweera D, Junod P, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67:2020\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3506_CR39","doi-asserted-by":"publisher","first-page":"e61297","DOI":"10.1371\/journal.pone.0061297","volume":"8","author":"GV Matthews","year":"2013","unstructured":"Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Petcharapirat P, et al. Quantitative HBsAg and HBeAg predict hepatitis b seroconversion after initiation of HAARTt in HIV-HBV coinfected individuals. PLoS One. 2013;8(4):e61297.","journal-title":"PLoS One"},{"key":"3506_CR40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/QAI.0000000000000149","volume":"66","author":"M Kang","year":"2014","unstructured":"Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, et al. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV\/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr. 2014;66:172\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3506_CR41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2014.05.030","volume":"61","author":"P Miailhes","year":"2014","unstructured":"Miailhes P, Maynard-Muet M, Leboss\u00e9 F, Carrat F, Bouix C, Lascoux-Combe C, et al. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. J Hepatol. 2014;61:761\u20139.","journal-title":"J Hepatol"},{"key":"3506_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/1319-3767.145320","volume":"20","author":"S Yu","year":"2014","unstructured":"Yu S, Zhou Q, Zhao XM, Yuan M, Wang CT, Cheng XG, et al. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol. 2014;20:350\u20135.","journal-title":"Saudi J Gastroenterol"},{"key":"3506_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1310\/hct1003-153","volume":"10","author":"T Lee","year":"2009","unstructured":"Lee T, N\u00fanez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials. 2009;10:153\u20139.","journal-title":"HIV Clin Trials"},{"key":"3506_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0000000000000927","volume":"72","author":"Y Li","year":"2016","unstructured":"Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, et al. Lamivudine monotherapy-based cart is efficacious for HBV treatment in hiv\/HBV coinfection when baseline HBV DNA <20,000 IU\/mL. J Acquir Immune Defic Syndr. 2016;72:39\u201345.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3506_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews. 2017;6:79.","journal-title":"Systematic Reviews"},{"key":"3506_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5009\/gnl15562","volume":"11","author":"Y-S Lim","year":"2017","unstructured":"Lim Y-S. Management of Antiviral Resistance in chronic hepatitis B. Gut and Liver. 2017;11:189\u201395.","journal-title":"Gut and Liver"},{"key":"3506_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.26686","volume":"59","author":"KM Kitrinos","year":"2014","unstructured":"Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434\u201342.","journal-title":"Hepatology"},{"key":"3506_CR48","unstructured":"AIDSinfo. Considerations for antiretroviral use in patients with coinfections. In: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http:\/\/aidsinfo.nih.gov\/guidelines Accessed 2 Apr 2018."},{"key":"3506_CR49","first-page":"376A","volume":"48","author":"J Heathcote","year":"2008","unstructured":"Heathcote J, Gane EJ, deMan RA, Sing C, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data en HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Hepatology. 2008;48:376A.","journal-title":"Hepatology"},{"key":"3506_CR50","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","volume":"139","author":"G Woo","year":"2010","unstructured":"Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218\u201329.","journal-title":"Gastroenterology"},{"key":"3506_CR51","doi-asserted-by":"publisher","first-page":"e68152","DOI":"10.1371\/journal.pone.0068152","volume":"8","author":"H Price","year":"2010","unstructured":"Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV\/HIV Coinfected patients: a systematic review and meta-analysis. PLoS One. 2010;8:e68152.","journal-title":"PLoS One"},{"key":"3506_CR52","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355.","journal-title":"Lancet"},{"key":"3506_CR53","unstructured":"World Health Organization. Hepatitis B. Geneva: WHO; 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ Accessed 23 May 2018."},{"key":"3506_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","volume":"49","author":"A Kau","year":"2008","unstructured":"Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634\u201351.","journal-title":"J Hepatol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3506-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:05:39Z","timestamp":1662422739000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3506"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3506-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,11,14]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for approval was waived as this study solely used published human data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"564"}}